GuidelineAnnals of oncology : official journal of the European Society for Medical Oncology2023
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
3 registry-linked trialsAbstract readPractice Guideline
In one paragraph
Guideline in Annals of oncology : official journal of the European Society for Medical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 418 papers, 6 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
418citing papers in PubMed, 6 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Cell-free DNA Methylation Liquid Biopsy for Diagnosis and Management of Biliary Tract Cancers
Supra-papillary Versus Trans-papillary Biliary Stenting in Malignant Peri-hilar Stenosis (SupraBilS): a Randomized Controlled Trial
NCT07635290 phase2active not recruitingnot on this mapstarted 2026, after this paper: background citation
A Phase II Clinical Trial of Anlotinib Combined With Cadonilimab and PULSAR in Previously Treated Advanced Unresectable or Metastatic Biliary Tract Cancer
Who cites it
418 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Routine Lymph Node Dissection in the Surgical Treatment of Primary Liver Tumors: a Systematic Review and Meta-Analysis.Journal of gastrointestinal cancer · 2026Pooled it
- Radiological Loco-Regional Treatments for Cholangiocarcinoma: A Systematic Review of the Literature.Liver international : official journal of the International Association for the Study of the Liver · 2026Pooled it
- Does adjuvant therapy improve survival in patients undergoing pancreaticoduodenectomy for distal cholangiocarcinoma? A systematic review, meta-analysis and meta-regression.Updates in surgery · 2026Pooled it
- Pooled it
- Exploring the impact of first-line durvalumab plus chemotherapy on advanced biliary tract cancer: a systematic review and meta-analysis.The oncologist · 2025Pooled it
- SEOM-GEMCAD-TTD clinical guidelines for biliary tract cancer (2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Guideline
- Domvanalimab plus zimberelimab in unresectable and immunotherapy refractory biliary tract cancers: a phase 2 trial.Nature communications · 2026Trial
- Trial
- Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Adjuvant tislelizumab, lenvatinib, and capecitabine for resected biliary tract cancer: a prospective phase II trial.BMC medicine · 2026Trial
- Percutaneous Endobiliary Cryobiopsy in Biliary Obstruction: Randomised Study (BICRYOB).Cardiovascular and interventional radiology · 2026Trial
- Locoregional gemcitabine plus surufatinib and camrelizumab in FGFR2-non-altered intrahepatic cholangiocarcinoma.Cell reports. Medicine · 2025Trial
- Tasurgratinib (E7090) for cholangiocarcinoma with fibroblast growth factor receptor 2 fusions/rearrangements: a multicenter, open-label, Phase 2 study.Japanese journal of clinical oncology · 2025Trial
- Sunitinib as Second-Line Treatment in Advanced Intrahepatic Cholangiocarcinoma: Results From the SUN-CK GERCOR Phase II Trial.Liver international : official journal of the International Association for the Study of the Liver · 2025Trial
- Trial
- Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI-SAFRADJU-2501).International journal of cancer · 2026Observational
- Development and Validation of a Crotonylation-Related Prognostic Risk Model for Cholangiocarcinoma Based on Integrative Transcriptome Analysis.Digestive diseases and sciences · 2026Article
- Molecular biomarkers for diagnosis, prognosis, precision therapy, and immunotherapy in cholangiocarcinoma, cHCC-CCA, and HCC.Hepatology communications · 2026Review
- Extended Lymphadenectomy is Associated with Better Survival Outcome in Resected T1b-T4 Gallbladder Cancer: A 505-Patient Cohort Study.Annals of surgical oncology · 2026Article
- Targeting adaptive EGFR feedback enhances the therapeutic efficacy of RMC-6236 in cholangiocarcinoma.Experimental hematology & oncology · 2026Article
358 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
12 authors.
A VogelDepartment of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover, Hannover, Germany.
J BridgewaterCancer Institute, University College London (UCL), London, UK.
J EdelineDepartment of Medical Oncology, CLCC Eugène Marquis, Rennes, France; Chemistry, Oncogenesis, Stress and Signaling (COSS), INSERM, University of Rennes, Rennes, France.
R K KelleyHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, USA.
H J KlümpenDepartment of Medical Oncology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.
D MalkaDepartment of Medical Oncology, Institut Mutualiste Montsouris, Paris, France; INSERM U1279, Université Paris-Saclay, Villejuif, France.
J N PrimroseUniversity Department of Surgery, University Hospital Southampton, Southampton, UK.
L RimassaDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
A StenzingerInstitute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
J W ValleDivision of Cancer Sciences, University of Manchester, Manchester, UK; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
M DucreuxINSERM U1279, Université Paris-Saclay, Villejuif, France; Department of Cancer Medicine, Gustave Roussy, Villejuif, France.
ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Funding
Cancer Research UK 4273
Abstract
PubMed holds no abstract for this paper.
Indexed as
Bile Duct NeoplasmsBiliary Tract NeoplasmsCholangiocarcinomaGallbladder NeoplasmsBile Ducts, IntrahepaticFollow-Up StudiesHumanscholangiocarcinomadiagnosisfollow-upgallbladder cancerprecision medicinetreatment
Identifiers
PMID
36372281What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.